The model of this application is a deployment of the model published by Thépaut et al. (2023) in the paper titled "PBPK modeling to support risk assessment of pyrethroid exposure in French pregnant women". Here, only the permethrin maternal internal concentrations are results/plot.

The p-PBPK model includes a maternal and a fetal sub-model (Fig. 1). The maternal sub-model includes 23 tissue compartments for the parent compounds. The fetal sub-model is connected to the maternal sub-model through the placenta and has 19 fetal compartments. This p-PBPK model was based on the lifetime model developed by Beaudouin et al. (2010) which was applied to pyrethroids by Quindroit et al. (2019) for adults only. In their model, Quindroit et al. (2019) modified the initial model to account for the pyrethroids’ kinetics and to include the kinetics of the metabolites. In our study, only the oral route was considered.

In this model, the organ growth for maternal and fetal parts of the model were described as in the lifetime model of Beaudouin et al. (2010). Since the volume of distribution increase during pregnancy, a hemodilution is observed in pregnant women. Hence, the equation describing hematocrit (HCT) was modified as proposed by Dallmann et al. (2017). Maternal cardiac output was corrected with HCT and increased during pregnancy. This increase in cardiac output leads to an increase in blood flow to all organs during pregnancy. Uterine blood flow was described using an equation developed by Dallmann et al. (2017). Concerning fetal blood flows, equations from Abduljalil et al. (2021) were applied in the model.

Compound specific parameters for parent compound were set using in vivo animal data, due to the lack of in vivo or in vitro human data. For permethrin, the tissue:blood partition coefficients in mother and fetus were obtained from a study in which a p-PBPK model was calibrated with toxicokinetic data in pregnant rats (Personne et al., 2021). In mothers, isomer specific values were determined whereas experimental data in fetuses did not allow to estimate isomers values. Placental partition coefficients for permethrin were set to the ones proposed by Personne et al. (2021) for permethrin. For maternal compartments such as the adipose tissue, brain and muscles, permethrin distribution accounts for permeability coefficients to describe the ability of the compound to reach the organ tissue from the blood circulation. These coefficients have been scaled from rat data (Godin et al., 2010; Willemin et al., 2016) to humans. Regarding metabolites excretion, the model considers the excretion of 3 metabolites: 3-PBA, cis-DCCA and trans-DCCA. Since 3-PBA is a common metabolite to various PYR, a parameter (Rate_Input_PBA) was taken into account to consider the part of 3-PBA coming from other exposure to PYR, therefore an additional source of 3-PBA was considered into the model.

Figure 1. Schematic representation of the p-PBPK model (from Thépaut et al. (2023)).

References:

Abduljalil, K., Pan, X., Clayton, R., Johnson, T.N., Jamei, M., 2021. Fetal physiologically based pharmacokinetic models: systems information on fetal cardiac output and its distribution to different organs during development. Clin. Pharmacokinet. 60,741–757.

Beaudouin, R., Micallef, S., Brochot, C., 2010. A stochastic whole-body physiologically based pharmacokinetic model to assess the impact of inter-individual variability on tissue dosimetry over the human lifespan. Regul. Toxicol. Pharmacol. 57, 103–116.

Dallmann, A., Ince, I., Meyer, M., Willmann, S., Eissing, T., Hempel, G., 2017. Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokineticmodeling in pregnancy. Clin. Pharmacokinet. 56, 1303–1330.

Godin, S.J., Devito, M.J., Hughes, M.F., Ross, D.G., Scollon, E.J., Starr, J.M., Setzer, R.W., Conolly, R.B., Tornero-Velez, R., 2010. *Physiologically based pharmacokinetic modeling of deltamethrin: development of a rat and human diffusion-limited model.*Toxicol. Sci. 115, 330–343.

Mirfazaelian, A., Kim, K.B., Anand, S.S., Kim, H.J., Tornero-Velez, R., Bruckner, J.V., Fisher, J.W., 2006. Development of a physiologically based pharmacokinetic model for deltamethrin in the adult male Sprague-Dawley rat. Toxicol. Sci. 93, 432–442.

Personne, S., Brochot, C., Marcelo, P., Corona, A., Desmots, S., Robidel, F., Lecomte, A.,Bach, V., Zeman, F., 2021. Evaluation of placental transfer and tissue distribution of cis- and trans-permethrin in pregnant rats and fetuses using a physiological-based pharmacokinetic model. Front. Pediatr. 9, 730383.

Quindroit, P., Beaudouin, R., Brochot, C., 2019. Estimating the cumulative human exposures to pyrethroids by combined multi-route PBPK models: application to the French population. Toxicol. Lett. 312, 125–138.

Sheets, L.P., Doherty, J.D., Law, M.W., Reiter, L.W., Crofton, K.M., 1994. Age-dependent differences in the susceptibility of rats to deltamethrin. Toxicol. Appl. Pharmacol. 126, 186–190.

Thépaut, E., Bisson, M., Brochot, C., Personne, S., Appenzeller, B.M.R., Zaros, C., Chardon, K., Zeman, F., 2024. PBPK modeling to support risk assessment of pyrethroid exposure in French pregnant women. Environ Res. 2024 Jun 15;251(Pt 1):118606.

Tornero-Velez, R., Mirfazaelian, A., Kim, K.B., Anand, S.S., Kim, H.J., Haines, W.T., Bruckner, J.V., Fisher, J.W., 2010. Evaluation of deltamethrin kinetics and dosimetry in the maturing rat using a PBPK model. Toxicol. Appl. Pharmacol. 244, 208–217.

Willemin, M.E., Desmots, S., Le Grand, R., Lestremau, F., Zeman, F.A., Leclerc, E., Moesch, C., Brochot, C., 2016. PBPK modeling of the cis- and trans-permethrin isomers and their major urinary metabolites in rats. Toxicol. Appl. Pharmacol. 294, 65–77.